ABSTRACT

Background: Plant based products are recognised as sources of drugs for treatment of diseases. Objective: The study aimed at predicting the physicochemical, pharmacokinetics, drug-likeness and toxicity of the compounds identified from the methanolic Encephalartos ferox fruit extract. Methods: The physicochemical, pharmacokinetics properties and bioactive scores of the compounds were predicted using SwissADME and Molinspiration computational tools. Drug-likeness of the compounds was evaluated based on the Lipinski rule of five (Ro5). In silico mutagenicity, carcinogenicity and inhibition of human ether-a-go-go-related (hERG) gene were also investigated using PreADMET web tool. Results: The physicochemical properties showed the compounds, except 9-Octadecenoic acid, 1, 2, 3-propanetriyl ester to adhere to Ro5. The evaluation of their inhibitory effects profile in several cytochrome P450 isozymes indicate that all the compounds are not the inhibitors of CYP2C19 and CYP3A4 whereas some inhibited CYP1A2, CYP2C9 and CYP2D6. The drug-likeness evaluation employed Ro5 as a filter and all compounds complied with it except for 9-Octadecenoic acid, 1, 2, 3-propanetriyl ester. About 50% of the tested compound were found to be safe as they did not exhibit antimutagenic and carcinogenic effects. Moreover, the risk of inhibition of hERG gene revealed to be low to medium risk depending on the compound. Conclusion: The calculated physicochemical and pharmacokinetic properties suggest that most of the compounds are safe and have promising oral bioavailability.

Key words: Compounds, Pharmacokinetic; Drug-likeness, Bioactive score, Toxicity.

INTRODUCTION

Infectious diseases continue to devastate the developing world by presenting high mortality and morbidity rates annually. Medicinal plants are the predominant sources of natural lead compounds used in drug discoveries and developments to combat the prevalence of infectious diseases. Their high potency and pharmacotherapeutic effects are owed to their diverse bioactive compounds. Among these compounds are alkaloids, saponins, tannins, glycosides and flavonoids. Thus, approximately 80% of the population in developing countries still rely on phytopharmaceuticals to prevent and treat different emerging and re-emerging infections.

Many lead compounds with very interesting pharmacological properties often fail to enter the market as a result of unsatisfactory drug-likeness properties and poor pharmacokinetic characteristics. Drugs are to be easily absorbed in the body and distributed to the targeted molecules. Moreover, they are to be easily metabolised and eliminated from blood stream without causing any toxic effects. These properties are summed up by the term ADME (absorption, distribution, metabolism and elimination) or better ADMET when toxicity studies are included. In addition, the lead compounds ought to possess the physicochemical properties set by different drug filters such as Lipinski’s rule of five (Ro5) to be regarded as drug-like compounds.

It is time consuming, tedious and costly to evaluate drug-likeness and ADMET parameters of lead compounds using conventional methods. Recently, computational assessments are adapted as they circumvent the high costs of unnecessary use of resources and time. Although computational methods are not confirmatory, they do provide information of the most likely drug-like compounds out of an array of compounds. Computational methods are well established in medicinal synthetic chemistry, however, their application in the field of natural compounds remain unexplored.

Encephalartos ferox is cycad belonging to the Zamiaceae family. It is endemic in northern Kwazulu-Natal, South Africa. The plant parts, especially the leaves are used as prophylaxis in the treatment of oestrogen-dependent tumour and diabetes. However, there are limited studies reporting on the medicinal properties of its fruit. Our previous study investigated the chemical composition of the E. ferox methanolic fruit extract. The gas chromatography mass spectrophotometry chromatogram profile revealed a total of eight volatile compounds namely cis-Vaccenic acid (1), 9-Octadecenoic acid, 1,2,3-propanetriyl ester (2), 4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy (3), 9-Hexadecenoic acid, 1,2,3-propanetriyl ester (2), 4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy (3), 9-Hexadecenoic acid (4) and Pentadecanoic acid (5). Other compounds were 10-Octadecenoic acid, methyl ester (6), Hexadecanoic acid, 2-hydroxy-1-(hydroxym) (7) and 11, 14-Eicosadienonic acid, methyl ester (8). These compounds have been recognised to possess...
pharmacological properties such as: anti-inflammatory, antimicrobial, hypolipidemic, anti-spasmodic, antioxidant, anti-proliferative, antidiabetic, anti-arthritic and anti-coronary activities. The reported pharmacological activities of these eight compounds are not solitary prerequisites for their extraction and commercialisation. To reach the market, these compounds ought to reveal satisfactory drug-likeness and pharmacokinetic properties. Thus, this study was designed to utilise the computational tools to predict the drug-likeness and pharmacokinetic parameters of the eight compounds previously identified from E. fruit. Moreover, the bioactivity was evaluated by Molinspiration computational tool.

RESULTS AND DISCUSSION

The lack of pharmacokinetic studies is one of the main hindrances in the commercialisation of the plant-based products. Thus, the study was designed to use computational methods to evaluate the physicochemical, pharmacokinetic and drug-likeness properties of the eight previously identified compounds from the methanolic fruit extract of Encephalartos ferox.

Physicochemical properties

All identified compounds have molecular weight in the acceptable range (MW ≤ 500) except for compound 2, which has the molecular weight of 885.43 g/mol. This implied that all the identified compounds with MW ≤ 500 have potential to be easily absorbed, diffused and transported when compared to compound 2. The drug-like compounds ought to have nHBA ≤ 10 and nHBD ≤ 5. The nHBA and nHBD for all tested compounds were found to be within the Lipinski’s limit range (Table 1). This implies that the compounds can be well absorbed or permeable from the gastrointestinal tract when they are administrated. The number of rotatable bonds is a measure of molecular flexibility and is one of the widely used filter during drug discovery process. In this study the number of rotatable bonds of each compound was counted and the results are displayed in Table 1. The highest rotatable bonds were observed with compound 2 (nRB = 53) followed by 7 (nRB = 18), 8 (nRB = 17), 6 (nRB = 16), 1 (nRB = 15), 4 (nRB = 13), 5 (nRB = 13) and 3 (nRB = 0). Compounds with good bioavailability have ≤ 15 rotatable bonds. Compound 1, 3, 4 and 5 fell within the acceptable range (nRB ≤ 15), indicative of their potential permeability and oral bioavailability. Other tested compounds showed high number of rotatable bonds (15 ≤ nRB), hence more flexibility and poor oral bioavailability.

Lipophilicity and solubility of the compounds

Lipophilicity influences the solubility, selectivity, potency, permeability and promiscuity of lead compounds. The cLogP of the compounds are illustrated in Table 1. Compound 3, 4, 5 and 7 adhered to the Ro5 (clogP ≤ 5), whereas compound 1, 2, 6 and 8 violated it (clogP > 5). High lipophilicity (clogP > 5) frequently leads to compounds with high rapid metabolic turnover, low solubility and poor absorption. Moreover, an increase in lipophilicity (clogP > 5) turns to increase the probability of compounds binding to hydrophobic protein targets other than the desired ones, consequently inducing toxic effects in biological systems. Solubility is one of the factors affecting drug absorption and distribution. The estimation of the aqueous solubility demonstrated that the identified compounds, except compound 2-which is insoluble, are highly to poorly soluble, depending on the LogS prediction model (Table 2). To be absorbed, compounds ought to be soluble in water so they can permeate across cell membranes. Thus, only compound 2 showed no probability of being absorbed and distributed.

MATERIALS AND METHODS

Physicochemical, pharmacokinetics and drug-likeness properties of the compounds

The canonical SMILES (simplified molecular input line entry system) strings of the eight identified compounds from methanolic E. ferox fruit extract, were procured from PubChem (https://pubchem.ncbi.nlm.nih.gov/compound). They were then incorporated into SwissADME tool. The physicochemical characters of the compounds such as molecular weight (MV), number of hydrogen bond acceptors (nHBA), number of hydrogen bond donors (nHBD) and number of rotational bonds (nRB) were then predicted. The ADME parameters that include octanol-water partition coefficient lipophilicity (cLogP), solubility, gastrointestinal absorption (GLA), blood brain barrier (BBB), p-glycoprotein (P-gp) substrate, inhibition of isoforms of cytochrome P450 (CYP), and skin permeability (LogKP) were estimated by SwissADME. Lipinski’s rule of five was applied to assess the drug-likeness of the compounds. The rule states that the drug-like compounds ought to have: MV ≤ 500 daltons, nHBA ≤ 10, nHBD ≤ 5 and clogP ≤ 5. Moreover, compounds are not accepted if they show more than one violation of these set limits.

Bioactivity scores of the compounds

The bioactivity scores of the compounds for molecules such as G protein coupled receptor (GPCR) ligand, ion channel modulator, kinase inhibitor, nuclear receptor ligand and protease inhibitor were evaluated using Molinspiration Online tool (http://www.molinspiration.com). Prior to prediction of bioactivity scores, the canonical SMILES strings of the compounds from were procured from PubChem and incorporated into Molinspiration tool.

Toxicity of the compounds

The toxicological properties of the compounds were calculated using an online server PreADMET (https://preadmet.bmdrc.kr/). The compounds were first drawn and then subjected for evaluation of toxicity by selecting TionAlert options. Thereafter, mutagenicity and carcinogenicity profiles of the compounds were noted.

Table 1: The physicochemical properties and lipophilicity of the identified compounds.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>Properties</th>
<th>Properties</th>
<th>CLogP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MV (g/mol)</td>
<td>nHBD</td>
<td>nHBA</td>
</tr>
<tr>
<td>1</td>
<td>282.46</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>885.43</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>144.13</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>254.41</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>242.40</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>296.49</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>330.50</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>8</td>
<td>322.53</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>
Pharmacokinetic properties

The gastrointestinal absorption (GIA) of the identified compounds was predicted and the results are described in Table 4. All the compounds, except for compound 2 and 8, revealed high probabilities of being absorbed in the gastrointestinal tract upon oral administration.33 The BBB is the microvascular endothelial cell layer of the brain which separates the brain from the blood.34 The compounds were evaluated for their ability to cross BBB and the results are shown in Table 4. According to the obtained results, 30% of the compounds exhibit capability to cross the BBB. The penetration across BBB is only mandatory for compounds targeting the central nervous system (CNS).35 Compound 1, 2, 3, 6 and 8 did not show potential to cross BBB, hence this can be an advantage as they have less likelihood to induce adverse effects in the CNS.35 P-glycoproteins (P-gp) are membrane transporters of compounds in the intracellular or extracellular directions.36 Almost all compounds, except compound 2 were estimated to be non substrates for P-gp. This implies that the compounds would not be affected by the efflux action of P-gp, which turns to eliminate compounds from cells, resulting in therapeutic failure because of lower concentrations than expected. Thus, only the efficacy of compound 2 has potential to be resisted in different target sites.37

Metabolism prediction of lead compounds is one of the main priorities during drug discovery process.38 The metabolism predictions of the compounds were done against five isozymes of cytochrome P450 (CYP) monooxygenase family namely; CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 and the results are displayed in Table 4. All compounds showed not to inhibit CYP2C19 and CYP3A4 whereas CYP2D6 was only inhibited by compound 7. About 50% of the compounds did not inhibit CYP2C9 while 37.5% did not obstruct CYP1A2. Cytochrome P450 monoxygenase plays a pivotal part in the brain which separates the brain from the blood.34 The compounds that might require transdermal administration. The LogKp of the compounds is presented in Table 3. All the compounds, except for compound 2 and 4, are expected to be impermeable as they had the negative LogKp values. This implies that only compound 2 and 4 could be effectively administered through the skin.37

Drug-likeness properties and bioavailability of the compounds

Poor oral absorption of drug molecules is observed if the compounds violate more than one of Ro5.40 Ro5 was used as a filter to identify compounds that have high probability of being drug candidates and the results are shown in Table 4. All compounds, except for compound 2, can be categorised as drug-like compounds. Due to the high molecular mass and lipophilicity, compound 2 failed to comply Lipinski rules of five. Bioavailability defines the extent and rate at which compounds administered enter systemic circulation and ultimately reach the targeted sites upon oral administration.41 The oral bioavailability results of the compounds are shown in Table 4. Most of the compounds have the bioavailable value of 0.55 and 0.56. The 0.55 and 0.56 values imply that the compounds adhere to Lipinski rule of five and have 55 and 56% probabilities of being bioavailable.23 Only compound 2 was classified as having low probability of attaining the bioavailability endpoints (≥ 0.5). Nevertheless, if compound 2 is to be used for drug discovery due to its therapeutic benefits, it ought to be modified to improve its bioavailability.

Bioactivity score

The computed bioactivity scores of the compounds are displayed in Table 5. The bioactivity scores for compounds as interpreted as active (scores > 0), moderately active (scores: -5.0-0.0) and inactive (bioactivity score < -5.0).43 Among the tested compounds, compound 1, 6, 7, and 8 were found to be active G protein coupled receptor ligands (≥ 0) while compounds 2, 3, 4 and 5 are moderate ligands. Compound 1 and 8 exhibited active activities as ion channel modulators (0.07

| Table 2: Solubility predictions of the identified compounds. |

<table>
<thead>
<tr>
<th>Properties</th>
<th>Compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>LogS (ESOL) Class</td>
<td>1</td>
</tr>
<tr>
<td>Moderately soluble</td>
<td>-5.41</td>
</tr>
<tr>
<td>Insoluble</td>
<td>-15</td>
</tr>
<tr>
<td>Poorly soluble</td>
<td>-15.94</td>
</tr>
<tr>
<td>LogS SILICOS-IT Class</td>
<td>-5.39</td>
</tr>
<tr>
<td>Moderately soluble</td>
<td>-17</td>
</tr>
</tbody>
</table>

| Table 3: The pharmacokinetic parameters of the identified compounds. |

<table>
<thead>
<tr>
<th>Compounds</th>
<th>GIA</th>
<th>BBB permeant</th>
<th>P-gp substrate</th>
<th>CYP1A2 inhibitor</th>
<th>CYP2C19 inhibitor</th>
<th>CYP2C9 inhibitor</th>
<th>CYP2D6 inhibitor</th>
<th>CYP3A4 inhibitor</th>
<th>LogKp (cm/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>High</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>-2.60</td>
</tr>
<tr>
<td>2</td>
<td>Low</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>4.2</td>
</tr>
<tr>
<td>3</td>
<td>High</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>-7.44</td>
</tr>
<tr>
<td>4</td>
<td>High</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>13.18</td>
</tr>
<tr>
<td>5</td>
<td>High</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>-3.07</td>
</tr>
<tr>
<td>6</td>
<td>High</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>-2.82</td>
</tr>
<tr>
<td>7</td>
<td>High</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>-3.96</td>
</tr>
<tr>
<td>8</td>
<td>Low</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>-2.66</td>
</tr>
</tbody>
</table>
and 0.06, respectively) whereas the other six demonstrated moderate activities, as potentials to modulate ion channels. Compound 1 is the most active compound against kinase enzyme with the bioactivity score of 0.00, while other compounds had moderate activity with bioactivity scores in a range of -0.14 to -0.42. These compounds, especially compound 1, have potential to treat infections caused by hyperactive protein kinases. Nuclear receptors are key regulators of various metabolic diseases such as diabetes. Based on our results, all compounds showed active (compound 1, 3, 5, 6, 7 and 8) to moderate (compound 2 and 4) potential to inhibit nuclear receptors. This implies that these compounds are promising therapeutic alternatives to treat some metabolic disorders. Active protease inhibition was predicted for three compounds (compound 1, 7 and 8) while the other compounds revealed moderate activity. The results reveal that the compounds can act as protease inhibitors.

Toxicological predictions

The toxicity assessment of compounds is an important step during drug discovery process. The toxicological predictions including mutagenicity, carcinogenicity and inhibition of hERG by the compounds are shown in Table 5. According to PreADMET, the negative prediction translates carcinogenic activity whereas positive means the compound does not have carcinogenic activity. About four compounds (compound 2, 6, 7 and 8) were found to be safe as they did not exhibit any mutagenic and carcinogenic effects. The compounds did also reveal to have low to medium probabilities of inhibiting hERG. The obstruction of the hERG gene is strongly associated with the prolonged QT syndrome, which often result in sudden heart attacks in humans. Based on these presumptions, all the compounds are safe for use as they show low to medium capabilities of blocking hERG gene.

CONCLUSIONS

It was observed that the majority of the compounds have good physicochemical profiles with several other ADMET properties. The drug-like property predictions showed that most of the compounds, except compound 2, comply to Ro5. Compound 2, 6, 7 and 8 are safe for use as they did not demonstrate any potential to be mutagenic and carcinogenic on the tested parameters. Moreover, all the compounds did show low to medium risks of inhibiting hERG. Furthermore, these predictive results should be validated by in vitro and in vivo toxicological approaches.

ACKNOWLEDGMENTS

The authors acknowledge the Research and Innovation Committee of the University of Zululand, for funding this research. The authors would like to also acknowledge the staff and postgraduate students in the Department of Biochemistry and Microbiology for their outstanding support.
CONFLICTS OF INTEREST
The authors declare no conflict of interest.

ABBREVIATIONS
GC-MS: gas chromatography-mass spectrometry; GC: gas chromatography; MS: mass spectrometry; E. ferox: Encephalartos ferox; GPCR: G protein coupled receptor; MV: molecular weight, nHBA: number of hydrogen bond acceptors; nHBd: number of hydrogen bond donors; nRB: number of rotational bonds; ADME: absorption, distribution, metabolism and elimination; cLogP: octanol-water partition coefficient lipophilicity; LogS: solubility; GIA: gastrointestinal absorption; BBB: blood brain barrier; P-gp: p-glycoprotein; CYP: cytochrome P450 (CYP); LogPK: skin permeability; hERG: ether-a-go-go related; Ro5: Lipinski rule of five.

REFERENCES
Maliehe, et al.: Computational Evaluation of ADMET Properties and Bioactive Score of Compounds from Encephalartos ferox


**GRAPHICAL ABSTRACT**

**Physicochemical properties** — **Drug-likeness** — **Bioactivity scores**

**Phytochemicals** — **in silico studies** — **Toxicity** — **Pharmacokinetic properties**

**ABOUT AUTHORS**

**Dr. TS Maliehe** holds a BSc degree in Biotechnology and BSc-Honours, MSc and PhD degrees in Microbiology from the University of Zululand. He was also a postdoctoral fellow in the same institution. His research expertise falls within the Environmental Microbiology with emphasis on wastewater treatment using microbial bioflocculants. He is an expert in bioactive compounds of health importance from microbial origin (endophytes) and plants. He is also well informed in Bioinformatics. He has collaborated with a large number of researchers and academics and published his work in highly rated accredited journals.

**Mr. PH Tsilo**, Holds a BSc degree in Biochemistry and Microbiology and BSc-Honours in Microbiology from the University of Zululand. Is currently doing his first year in MSc degree in Microbiology from the same institution. His research project is on wastewater treatment using bioflocculants.

**Mr. Jabulani Siyabonga Shandu**

**Position:** Lecturer  
**Phone:** (035)902-6201  
**Email:** Shanduj@unizulu.ac.za  
**Building & Room:** Room, Sc.255, 1ST Floor, Natural Science Building  
**Biography:**  
Mr J.S. Shandu is a lecturer in the field of Microbiology at the University of Zululand at kwa-Dlangezwa campus. He holds an MSc. degree in Microbiology. His research interests are in phytomedicine and aquatic microbiology.  
**Qualifications:** BSc, BSc (Hons.), MSc. (Microbiology). University of Zululand.  
**Research interests:**  
Medicinal plant properties and Water quality monitoring  
**Professional membership:**  
• SASM-KZN  
**Research Databases / Publications:**  
Has published on several academic journals since 2008, particularly in phytomedicine.

**Cite this article:** Maliehe TS, Tsilo PH, Shandu JS. Computational Evaluation of ADMET Properties and Bioactive Score of Compounds from Encephalartos ferox. Pharmacogn J. 2020;12(6):1357-62.